An autopsy case of bronchiolitis obliterans as a previously unrecognized adverse event of afatinib treatment

详细信息    查看全文

• 作者：Nobuhiro Kanaji ; MD ; PhD^a ; ^{kanaji@med.kagawa-u.ac.jp} ; Yoichi Chiba ; MD ; PhD^b ; ^{ychiba@med.kagawa-u.ac.jp} ; Akira Sato ; MD ; PhD^c ; ^{satoh@kagawa.coop} ; Masaki Ueno ; MD ; PhD^b ; ^{masaueno@med.kagawa-u.ac.jp} ; Akira Tadokoro ; MD ; PhD^a ; ^{tadokoro@med.kagawa-u.ac.jp} ; Nobuyuki Kita ; MD^a ; ^{kitan0@med.kagawa-u.ac.jp} ; Tomoya Ishii ; MD ; PhD^a ; ^{tishii@med.kagawa-u.ac.jp} ; Naoki Watanabe ; MD^a ; ^{naoki-w@med.kagawa-u.ac.jp} ; Norimitsu Kadowaki ; MD ; PhD^a ; ^{kado@med.kagawa-u.ac.jp} ; Shuji Bandoh ; MD ; PhD^a ; ^{sbandoh@med.kagawa-u.ac.jp}
• 关键词：BO ; bronchiolitis obliterans ; TKI ; tyrosine kinase inhibitor ; EGFR ; epidermal growth factor receptor ; NSCLC ; non-small cell lung cancer ; ILD ; interstitial lung disease ; FEV1 ; forced expiratory volume in 1s
• 刊名：Respiratory Investigation
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：55
• 期：1
• 页码：58-62
• 全文大小：1422 K
• 卷排序：55

文摘

Interstitial lung disease is a well-known pulmonary adverse event that occurs during epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy and results in restrictive ventilatory dysfunction. However, obstructive changes such as those associated with bronchiolitis obliterans (BO) have never been reported as adverse events resulting from the use of any approved EGFR-TKI. This report documents an autopsy case of BO that developed during afatinib treatment for adenocarcinoma of the lung. Knowledge of the possibility of this fatal adverse event is important for adequate follow-up of patients with lung cancer undergoing afatinib treatment.